Assessing the impact of dabigatran and warfarin on health-related quality of life: Results from an RE-LY sub-study

International Journal of Cardiology

Volumn 168, Issue 3, 2013, Pages 2540-2547

  Monz, B U ^a   Connolly, S J ^b   Korhonen, M ^c   Noack, H ^a   Pooley, J ^d  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

^c Boehringer Ingelheim Finland Ky   (Finland)

^d UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Atrial fibrillation; Dabigatran; Health related quality of life; Oral anticoagulation; Warfarin

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH IMPACT ASSESSMENT; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CLINICAL TRIAL; CONTROLLED STUDY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; WARFARIN;

EID: 84885576131     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.03.059     Document Type: Article

References (50)

1. M.B. Iqbal, A.K. Taneja, G.Y. Lip, and M. Flather Recent developments in atrial fibrillation BMJ 330 7485 2005 238 243
2. A.S. Go, E.M. Hylek, and K.A. Phillips Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 18 2001 2370 2375
3. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 8 1991 983 988
4. S. Penado, M. Cano, O. Acha, J.L. Hernandez, and J.A. Riancho Atrial fibrillation as a risk factor for stroke recurrence Am J Med 114 3 2003 206 210
5. W. Rosamond, K. Flegal, and K. Furie Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 117 4 2008 e25 e146
6. J.J. Caro, K.F. Huybrechts, and I. Duchesne Management patterns and costs of acute ischemic stroke: an international study. For the Stroke Economic Analysis Group Stroke 31 3 2000 582 590
7. P.L. Kolominsky-Rabas, P.U. Heuschmann, and D. Marschall Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project Stroke 37 5 2006 1179 1183
8. S.V. Sorensen, S. Dewilde, D.E. Singer, S.Z. Goldhaber, B.U. Monz, and J.M. Plumb Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation Am Heart J 157 6 2009 1064 1073
9. H.J. Lin, P.A. Wolf, and M. Kelly-Hayes Stroke severity in atrial fibrillation. The Framingham Study Stroke 27 10 1996 1760 1764
10. S. Stewart, C.L. Hart, D.J. Hole, and J.J. McMurray A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study Am J Med 113 5 2002 359 364
11. O. Rivero-Arias, M. Ouellet, A. Gray, J. Wolstenholme, P.M. Rothwell, and R. Luengo-Fernandez Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome Med Decis Making 30 3 2010 341 354
12. V. Diaz-Tapia, J. Gana, M. Sobarzo, A. Jaramillo-Munoz, and S. Illanes-Diez Study on the quality of life in patients with ischaemic stroke Rev Neurol 46 11 2008 652 655
13. S.L. Paul, J.W. Sturm, H.M. Dewey, G.A. Donnan, R.A. Macdonell, and A.G. Thrift Long-term outcome in the North East Melbourne Stroke Incidence Study: predictors of quality of life at 5 years after stroke Stroke 36 10 2005 2082 2086
14. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 12 2007 857 867
15. G.H. Guyatt, E.A. Akl, and M. Crowther Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 7S 47S
16. Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), European Heart Rhythm Association, and European Association for Cardio-Thoracic Surgery Guidelines for the management of atrial fibrillation Eur Heart J 31 19 2010 2369 2429
17. K.L. Furie, S.E. Kasner, and R.J. Adams Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American heart association/American stroke association Stroke 42 1 2011 227 276
18. L.B. Goldstein, C.D. Bushnell, and R.J. Adams Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 42 2 2011 517 584
19. E.M. Hylek, A.S. Go, and Y. Chang Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 11 2003 1019 1026
20. D.E. Singer, G.W. Albers, and J.E. Dalen Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th edition) Chest 133 6 Suppl. 2008 546S 592S
21. A.M. Holbrook, J.A. Pereira, and R. Labiris Systematic overview of warfarin and its drug and food interactions Arch Intern Med 165 10 2005 1095 1106
22. A. Tachjian, V. Maria, and A. Jahangir Use of herbal products and potential interactions in patients with cardiovascular diseases J Am Coll Cardiol 55 6 2010 515 525
23. J. Ansell, J. Hirsh, and E. Hylek Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th edition) Chest 133 6 Suppl. 2008 160S 198S
24. M. Jones, P. McEwan, C.L. Morgan, J.R. Peters, J. Goodfellow, and C.J. Currie Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population Heart 91 4 2005 472 477
25. I.M. Ogilvie, N. Newton, S.A. Welner, W. Cowell, and G.Y. Lip Underuse of oral anticoagulants in atrial fibrillation: a systematic review Am J Med 123 7 2010 638 645 [e4]
26. I.M. Ogilvie, S.A. Welner, W. Cowell, and G.Y. Lip Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation Am J Cardiol 108 1 2011 151 161
27. National Institute for Health and Clinical Excellence Atrial fibrillation: national clinical guideline for management in primary and secondary care Clinical guideline 36 2006 Available from: http://www.nice.org. uk/nicemedia/pdf/cg036fullguideline.pdf
28. T.P. Baglin, D. Cousins, D.M. Keeling, D.J. Perry, and H.G. Watson Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency Br J Haematol 136 1 2007 26 29
29. J. Stangier Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate Clin Pharmacokinet 47 5 2008 285 295
30. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 12 2009 1139 1151
31. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, P.A. Reilly, and L. Wallentin Randomized evaluation of long-term anticoagulation therapy I. Newly identified events in the RE-LY trial N Engl J Med 363 19 2010 1875 1876
32. M.D. Ezekowitz, S. Connolly, and A. Parekh Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran Am Heart J 157 5 2009 805 810 [810 e1-2.]
33. P. Dolan Modeling valuations for EuroQol health states Med Care 35 11 1997 1095 1108
34. P. Kind, G. Hardman, and S. Macran UK population norms for EQ-5D Discussion paper 172 1999 The University of York Centre for Health Economics York, UK
35. A.K. Roalfe, T.L. Bryant, and M.H. Davies A cross-sectional study of quality of life in an elderly population (75 years and over) with atrial fibrillation: secondary analysis of data from the Birmingham Atrial Fibrillation Treatment of the Aged study Europace 14 10 2012 1420 1427
36. P.G. Steg, S. Alam, and C.E. Chiang Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry Heart 98 3 2012 195 201
37. S.J. Walters, and J.E. Brazier Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D Qual Life Res 14 6 2005 1523 1532
38. J. Berg, P. Lindgren, R. Nieuwlaat, O. Bouin, and H. Crijns Factors determining utility measured with the EQ-5D in patients with atrial fibrillation Qual Life Res 19 3 2010 381 390
39. N.J. Davis, H.H. Billett, H.W. Cohen, and J.H. Arnsten Impact of adherence, knowledge, and quality of life on anticoagulation control Ann Pharmacother 39 4 2005 632 636
40. B.F. Gage, A.B. Cardinalli, and D.K. Owens The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life Arch Intern Med 156 16 1996 1829 1836
41. S.V. Sorensen, A.R. Kansal, and S. Connolly Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective Thromb Haemost 105 5 2011 908 919
42. A.R. Kansal, S.V. Sorensen, and R. Gani Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation Heart 98 7 2012 573 578
43. National Institute for Health and Clinical Excellence Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation Final appraisal determination NICE technology appraisal guidance 249 2012 Available from: www.nice.org.uk/ta249
44. J.V. Freeman, R.P. Zhu, and D.K. Owens Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Ann Intern Med 154 1 2011 1 11
45. H. Kamel, S.C. Johnston, J.D. Easton, and A.S. Kim Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack Stroke 43 3 2012 881 883
46. S.V. Shah, and B.F. Gage Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Circulation 123 22 2011 2562 2570
47. J. Pink, S. Lane, M. Pirmohamed, and D.A. Hughes Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses BMJ 343 2011 [d6333]
48. T. Davidson, M. Husberg, M. Janzon, J. Oldgren, and L.A. Levin Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden Eur Heart J 43 2012 881 883
49. L.K. Langkilde, M. Bergholdt Asmussen, and M. Overgaard Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark J Med Econ 15 4 2012 695 703
50. K. McKeage Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation Pharmacoeconomics 30 9 2012 841 855